$15.73 Billion Cancer Biomarkers Market by Profiling Technology, Biomolecules, Cancer Type, Application - Global Opportunity Analysis and Industry Forecast 2014-2022 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Cancer Biomarkers Market by Profiling Technology, Biomolecules, Cancer Type, Application - Global Opportunity Analysis and Industry Forecast, 2014-2022" report to their offering.

The market size of the global cancer biomarkers market was valued at $6,521 million in 2015 and is estimated to grow at a CAGR of 13% over the forecast period to reach $15,737 million in 2022.

The global cancer biomarkers market is segmented based on profiling technology, biomolecules, cancer type, application, and geography. By profiling technology, the market is segmented into omic technologies, imaging technologies, immunoassays and cytogenetics based tests. Based on biomolecules, the market is segmented into genetic biomarkers, protein biomarkers, and glycoprotein biomarkers. Amongst these, genetic biomarkers are widely used in the market owing to better diagnostic and therapeutic usage as compared to protein and glycoprotein biomarkers.

Market growth is attributed to the increasing incidences of cancers such as lung cancer, breast cancer, and prostate cancer among others coupled with growing importance of biological and targeted drug therapies and technological advancements in the field of cancer treatment. However, unregulated government laws and reimbursement policies; as well as high cost of drug development and threat of failure are anticipated to have an adverse effect on the market growth. Nevertheless, advancement in cancer drugs research and significant unmet need in cancer diagnosis are estimated to overshadow these restraints.

KEY MARKET SEGMENTS:

By Profiling Technology

  • Omic Technologies
  • Imaging Technologies
  • Immunoassays
  • Cytogenetics Based Tests

By Biomolecules

  • Genetic Biomarkers
  • Protein Biomarkers
  • Glycoprotein Biomarkers

By Cancer Type

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Stomach Cancer
  • Other Cancers

By Application

  • Diagnostics
  • Drug Discovery and Development
  • Prognostics
  • Risk Assessment
  • Others

Companies Mentioned

  • F.Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • GlaxoSmithKline plc
  • Novartis AG
  • Merck & Co., Inc.
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer, Inc.
  • Qiagen N.V.
  • Genomic Health, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/fp3zv7/cancer_biomarkers

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biomarkers

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biomarkers